Roche to Acquire PathAI for Up to $1.05 Billion to Expand Digital Pathology

Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry. The transaction is expected to close in the second half of 2026, subject to customary antitrust and regulatory approvals, after which the acquired entity will join Roche’s Diagnostics division. Under the terms, Roche will pay USD 750 million upfront with additional milestone payments of up to USD 300 million.

PathAI’s AISight Image Management System (IMS) is recognized as an efficient, user‑friendly software interface that integrates advanced analysis and workflow capabilities directly within the digital pathology laboratory. Digital pathology enables the creation of high‑resolution images from tissue slides, allowing pathologists to use AI tools that facilitate diagnostic workflows and provide patients with faster results. Roche intends to scale the AISight IMS solution globally as part of its digital pathology portfolio.

Image:The transaction is expected to close in the second half of 2026, with Roche paying USD 750 million upfront and up to USD 300 million in additional milestone payments

The combined offering is positioned to strengthen companion diagnostics and accelerate clinical therapy development by uniting Roche’s global diagnostics footprint with PathAI’s AI platform. According to the companies, bringing these capabilities together is expected to foster discovery of new biomarkers, potential drug targets, and novel diagnostic tools that add value for biopharma partners. The agreement builds on a partnership established in 2021 and expanded in 2024 to include development of AI‑enabled companion diagnostic algorithms, supporting a broader move toward personalized healthcare.

“Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,” said Matt Sause, CEO of Roche Diagnostics. “Bringing PathAI into Roche Diagnostics will allow us to combine their best-in-class digital pathology tools with our leading oncology diagnosis platforms to deliver better insights for physicians and potentially better outcomes for patients worldwide.”

Andy Beck, CEO and Co‑Founder of PathAI, said: “Joining forces with Roche marks a new era for PathAI, enabling us to realise our mission of improving patient outcomes through AI-powered pathology at unprecedented scale and speed. Roche's global infrastructure and expertise will bring our digital diagnostics technology to patients worldwide.”